BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Biswas M, Sawajan N, Rungrotmongkol T, Sanachai K, Ershadian M, Sukasem C. Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 Therapies. Front Pharmacol 2022;13:835136. [DOI: 10.3389/fphar.2022.835136] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Afewerki S, Stocco TD, Rosa da Silva AD, Aguiar Furtado AS, Fernandes de Sousa G, Ruiz-Esparza GU, Webster TJ, Marciano FR, Strømme M, Zhang YS, Lobo AO. In vitro high-content tissue models to address precision medicine challenges. Mol Aspects Med 2022;91:101108. [PMID: 35987701 DOI: 10.1016/j.mam.2022.101108] [Reference Citation Analysis]
2 Rochette L, Dogon G, Rigal E, Zeller M, Vergely C, Cottin Y. GDF15 : A modulator of immunity and a predictive biomarker of cardiovascular events : A strategy in COVID-19. Ann Cardiol Angeiol (Paris) 2023;72:41-3. [PMID: 36163282 DOI: 10.1016/j.ancard.2022.09.001] [Reference Citation Analysis]
3 Manóchio C, Torres-Loureiro S, Scudeler MM, Miwa B, Souza-Santos FC, Rodrigues-Soares F. Theranostics for COVID-19 Antiviral Drugs: Prospects and Challenges for Worldwide Precision/Personalized Medicine. OMICS 2023;27:6-14. [PMID: 36602768 DOI: 10.1089/omi.2022.0151] [Reference Citation Analysis]
4 Wang R, Sun N, Yang J, Bao S, Yang W, Wang Y, Hu Y. Solubility determination and thermodynamic model analysis of nevirapine in different organic solvents from 278.15 K to 328.15 K. Journal of Molecular Liquids 2022;365:120173. [DOI: 10.1016/j.molliq.2022.120173] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Zheng W, Tian E, Liu Z, Zhou C, Yang P, Tian K, Liao W, Li J, Ren C. Small molecule angiotensin converting enzyme inhibitors: A medicinal chemistry perspective. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.968104] [Reference Citation Analysis]
6 Al-mahayri ZN. Pharmacogenomics at the post-pandemic: If not now, then when? Front Pharmacol 2022;13:1013527. [DOI: 10.3389/fphar.2022.1013527] [Reference Citation Analysis]
7 Yao M, Huang X, Guo Y, Zhao JV, Liu Z. Disentangling the common genetic architecture and causality of rheumatoid arthritis and systemic lupus erythematosus with COVID-19 outcomes: genome-wide cross trait analysis and bi-directional Mendelian randomization study.. [DOI: 10.1101/2022.06.10.22276268] [Reference Citation Analysis]
8 Al-Taie A, Denkdemir FR, Sharief Z, Buyuk AS, Şardaş S. The Long View on COVID-19 Theranostics and Oral Antivirals: Living with Endemic Disease and Lessons from Molnupiravir. OMICS 2022;26:324-8. [PMID: 35580151 DOI: 10.1089/omi.2022.0045] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
9 Milani D, Caruso L, Zauli E, Al Owaifeer AM, Secchiero P, Zauli G, Gemmati D, Tisato V. p53/NF-kB Balance in SARS-CoV-2 Infection: From OMICs, Genomics and Pharmacogenomics Insights to Tailored Therapeutic Perspectives (COVIDomics). Front Pharmacol 2022;13:871583. [DOI: 10.3389/fphar.2022.871583] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]